Document is current

Article History

Received: 16 June 2025

Accepted: 1 July 2025

First Online: 26 August 2025

Declarations

:

: The study will be conducted in accordance with the principles of the Helsinki Declaration Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 updated to its latest version Fortaleza, Brazil, October 2013 (Appendix 17). With the Good Clinical Practice (GCP) standards issued by the Working Party on Medicinal Product Efficacy of the European Economic Community (1990) (CPMP/ICH/135/95) and the laws and regulations in force in Europe.

: Not applicable.

: MEMM has received honoraria as consultant from Boehringer Ingelheim España SA. JM and JS have filed a patent of the afatinib use to FA patients with HNSCC. J.S. has signed agreements in the last 3 years (advisory boards, service provision, research collaboration, or material transfer) with Boehringer Ingelheim, Glaxo Smith Kline, Moderna Therapeutics, Roche, Rocket Pharmaceuticals and Pfizer. All remaining authors declare that they have no competing interests.